- Lifecore Biomedical, Inc. (NASDAQ: LFCR) is set to release its Q1 financial results on May 6, 2026, with expectations for $25.96 million in revenue and an EPS of -$0.27.
- Barrington has raised its price target for Lifecore Biomedical to $6.00, indicating a potential 17.19% upside from its recent trading price of $5.12.
- Despite a negative P/E ratio of -5.69, the company exhibits a strong Current Ratio of 3.49, balancing its high Debt-to-Equity ratio of 4.23.
Lifecore Biomedical, Inc. (NASDAQ: LFCR) is scheduled to report its first-quarter financial results on May 6, 2026. As a leading contract development and manufacturing organization (CDMO), the company specializes in making sterile injectable pharmaceutical products for other firms. Senior management will host a webcast to discuss the company’s financial performance and strategic outlook.
Ahead of the upcoming earnings announcement, the firm Barrington raised its price target for Lifecore Biomedical to $6.00 from $5.50. A price target is an analyst’s estimate of a stock’s future value and a key indicator for investors. When this was published, the stock traded at $5.12, suggesting a potential upside of 17.19% if it reaches the new target.
For the upcoming financial report, the market expects revenue of approximately $25.96 million. The consensus earnings per share (EPS) estimate is -$0.27. This expected loss is consistent with Lifecore Biomedical’s negative Price-to-Earnings (P/E) ratio of -5.69, which indicates the company is not currently profitable.
The company’s valuation can also be viewed through its sales performance. Lifecore Biomedical has a Price-to-Sales ratio of 1.31 and an Enterprise Value to Sales ratio of 2.17. These key financial metrics are often used by investors to value companies that are generating revenue but have not yet achieved profitability.
Regarding its financial structure, Lifecore Biomedical has a Debt-to-Equity ratio of 4.23, showing it uses significant debt to finance its operations. On the other hand, the company has a healthy Current Ratio of 3.49. This suggests Lifecore Biomedical has a strong ability to meet its short-term financial obligations, indicating good liquidity.
